Cargando…
Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS
Autores principales: | Dake, Michael D., Ansel, Gary M., Lottes, Aaron E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966343/ https://www.ncbi.nlm.nih.gov/pubmed/32027000 http://dx.doi.org/10.1186/s42155-019-0069-x |
Ejemplares similares
-
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices
por: Dake, Michael D., et al.
Publicado: (2019) -
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent
por: Dake, Michael D., et al.
Publicado: (2020) -
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
por: Dake, Michael D., et al.
Publicado: (2016) -
First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study
por: Ye, Wei, et al.
Publicado: (2022) -
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results
por: Kichikawa, Kimihiko, et al.
Publicado: (2018)